SCD411-CP101

A Phase III Randomized, Double Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics Pharmacokinetics, and Immunogenicity between SCD411 and Eylea ® in Subjects with Neovascular Age -related Macular Degeneration.

Related Publications

Our Affiliates